Spin offs

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of new therapeutic strategies based on peptidic protease inhibition. Iproteos is developing peptidic protease inhibitors for the treatment of CNS diseases.

<p>Omnia</p>

Omnia Molecular (Omnia) designs and develops antiinfectives targeted at difficult-to-treat infections. Lead compounds are synthesized and optimized using a proprietary technology platform and are proven effective in several biological assays. Final proof of concept is conducted in animal infection models.

IRB Barcelona Spin offs

Innovation projects

Innovation projects

<p>Institució Cerca</p>

The Premi Pioner seeks to recognize researchers at CERCA centres who, in the last 18 months, have defended a doctoral thesis that has a clear orientation towards launching or strengthening a technology or product of industrial or commercial interest or that can make a significant contribution to the development of public policies. In 2015, Benjamí Oller, former PhD student in Prof. Ernest Giralt’s lab, was awarded this prize for his thesis, entitled “From bee venom to blood-brain barrier shuttles. Development of minimized apamin derivatives for brain delivery of antibodies and other cargoes”.

More information on this news.

The type of high-risk/high-gain research at the frontiers of knowledge that the ERC promotes often generates unexpected or new opportunities for commercial and societal applications. The ERC is committed to ensure the full exploitation of the excellent, useful ideas it funds. The Proof of Concept funding helps ERC grant-holders bridge the gap between their research and the earliest stage of a marketable innovation.

 

VALUNI 2015 aims to encourage action plans of marketing units to promote technology commercialization via the licensing of patents and/or creation of technology-based companies. Furthermore, it seeks to strengthen technology projects and marketing activities in order to ensure effective technology transfer to the productive sector. The Innovation Department was granted this funding for the project INNOVal 2015.

 

<p>la caixa fundacion</p>

BiomedTec is an IRB Barcelona internal programme supported by the Obra Social la Caixa and devoted to validate early-stage technologies from all disciplines. The development of the BiomedTec programme will foster the transfer of scientific results to the market, thus improving the quality of life of patients with cancer.

The first call was in 2012 and devoted to cancer. Due to the success of this first call, applications were broadened to all therapeutic areas. From the second call onwards it was officially denominated BiomedTec.

The Innovation Department is working to assure the continuation of the programme for the forecoming years.

<p>botin fundacion</p>

The Technology Transfer Programme run by the Botín Foundation offers research groups financial and management resources with the aim to ensure the dynamic and effective transfer of knowledge to society and the productive sector. Two IRB Barcelona researchers, namely Drs. Modesto Orozco and Joan Guinovart, were awarded this initiative in recent years. In 2013 and 2014, Drs. Eduard Batlle and Raúl Méndez have, respectively, also been invited to join this prestigious programme.

News

<p>Breast tumours have high levels of LIPG expression (F Slebe, IRB Barcelona)</p>
5 Apr 2016

A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and in collaboration with hospitals around Spain and the Universitat Rovira i Virgili (URV) has unveiled breast

<p>Microscopic structure of mouse testicle tissue (P.Mikolcevic, IRB Barcelona)</p>
30 Mar 2016

Published today in Nature Communications, a study by scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by ICREA researcher Angel R.

9 Mar 2016

”la Caixa” has led a 2.2 million Euro investment round in the Inbiomotion company, a spin off founded by the ICREA Research Rrofesso

9 Mar 2016

El Periódico”, “La Vanguardia”, “Ara”, and other media, report on the new round of funding received by the biotech company Inbiomotion

Testimonial

Contact

Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193